Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.2 CHF | -1.05% | -3.72% | -0.74% |
Mar. 26 | Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024 | |
Mar. 26 | Switzerland's SKAN Group Logs Improved FY23 Profit, Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 55% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.43 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 4.31 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.74% | 1.99B | - | ||
+73.46% | 12.41B | B- | ||
-15.61% | 8.23B | C+ | ||
+3.88% | 6.46B | C- | ||
+14.69% | 5.5B | D+ | ||
-5.53% | 5.33B | B | ||
+42.58% | 5.1B | - | ||
-32.61% | 2.54B | C | ||
+10.80% | 1.99B | - | ||
+10.31% | 1.77B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SKAN Stock
- Ratings SKAN Group AG